top of page

Cyclomics appoints advisory board

14 dec. 2023

Cyclomics has established an advisory board chaired by Joris Schuurmans, featuring experienced members from the molecular cancer diagnostics and life sciences investment sectors, to guide the company's growth and development.

Cyclomics is pleased to announce that it has established its advisory board to help the company to shape its strategy for continued growth and development. The advisory board is chaired by Joris Schuurmans, a seasoned executive with long-standing experience in molecular cancer diagnostics, currently serving as Chief Development Officer at SkylineDx, and is furthermore comprised of experienced members with valuable backgrounds: Nicky Rijk-Vogels (Chief Business Officer at Starfish Innovations, fund manager at Swanbridge Capital and several advisory roles, with a strong background in life science investment), Dirk Pollet (former CEO of Multiplicom, experienced executive with a background at Fujirebio, Abbott, currently serving in various boards) and Léon van Kempen (Professor of Molecular Diagnostics at Antwerp University Hospital). 



“We are very happy with such a strong team of advisors and look forward to their support and advise for growing Cyclomics”, says Alessio Marcozzi, founder and R&D director of Cyclomics. “Cyclomics is an innovative company that has demonstrated to develop valuable novel molecular and bioinformatic solutions in the cancer diagnostic space”, says Joris Schuurmans. “I am committed to chair the advisory team to help Cyclomics expand its technology portfolio and grow the company to bring its technology to the market.”

bottom of page